POLE and sarcoma: Our analysis revealed that in the 349 patients of MSKCC dataset, sarcoma patients had significantly less mutations than JiShuiTan cohort in MAP3K1, CREBBP, FAT1, MCL1, MEF2B, POLE, RUNX1, NOTCH2, and AXIN1 (Figure 3A).